Announced

Completed

Angelor led a €22m Series A round in Brenus Pharma.

Synopsis

Angelor, a venture capital firm, led a €22m Series A round in Brenus Pharma, a biotech company specializing in the development of cancer vaccines, with participation from UI Investissement and Crédit Agricole. We are proud to lead this strategic transaction for Brenus Pharma to support the clinical development of their cancer vaccines, including STC-1010, the first and most advanced program to emerge from the platform. We look forward to joining Paul and his exceptional team in transforming Brenus into a global player in precision immuno-oncology, bringing solutions to millions of patients experiencing treatment failure, and contributing to the development of the French biotherapeutics industry,” Marie Chambodut, Angelor Partner, and Investment Director.

Principals

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US